Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood marker may flag dangerous preeclampsia early

NCT ID NCT06413576

First seen Apr 11, 2026 · Last updated Jun 19, 2026 · Updated 6 times

Summary

This study looked at 70 pregnant women with preeclampsia to see if higher homocysteine levels in the blood are linked to more severe complications. Researchers measured homocysteine using a standard lab test and compared it to how serious each patient's condition was. The goal is to find a simple way to identify which patients need closer monitoring.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRE-ECLAMPSIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ain shams University

    Cairo, Cairo Governorate, 11591, Egypt

  • Ain shams university

    Cairo, Cairo Governorate, Egypt

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If homocysteine levels reliably indicate preeclampsia severity, doctors could use a simple blood test to identify high-risk patients earlier.

What could go wrong

This is a small, completed observational study, not a treatment trial. The results may not apply to all preeclampsia patients, and homocysteine may not be a strong enough marker on its own.

Conditions

The condition(s) this trial relates to.

Critical Illness preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.